Business
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, at 8:30 AM Eastern Time. C
About this update from Taysha Gene Therapies, Inc.
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, at 8:30 AM Eastern Time. Conference Call Details Tuesday, August 12, at 8:30 AM Eastern Time / 7:30 AM Central Time Toll Free: 877-407-0792 International: 201-689-8263 Conference ID: 13754869 Webcast: https://ir.tayshagtx.com/news-events/events-presentations About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com . Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. [email protected] Media Contact: Carolyn Hawley Inizio Evoke [email protected]
View stock analysis, news, and events for Taysha Gene Therapies, Inc.